Medical Expertise at Medical Aesthetics & Lasers
Medical Aesthetics & Lasers is led by Ayaz Khan, MD , an experienced physician who has practiced aesthetic medicine, pain management, and addiction medicine in the United States since 2004. Dr. Khan has completed advanced medical training in anesthesiology and surgery and has additional training and certifications in aesthetic medicine. His multidisciplinary medical background informs a patient-centered approach to aesthetic and wellness treatments.
The most popular advice about BHRT for men is often the least useful: treat fatigue, low motivation, or normal aging with “bioidentical” hormones and expect vitality to return. That approach reverses the proper order of care. Testosterone therapy should begin with a documented clinical problem, not a product pitch or a symptom checklist.
Whether you have male hypogonadism, meaning compatible symptoms alongside consistently low testosterone confirmed with appropriate testing, is the key question. Once treatment starts, the work isn't finished. Dose timing, hematocrit, prostate assessment, cardiovascular risk, fertility goals, and symptom response all determine whether therapy remains appropriate.
Table of Contents
- Why BHRT for Men Starts With the Right Diagnosis
- Who Actually Qualifies for Male Hormone Therapy
- Comparing FDA-Approved and Compounded Options
- Benefits Men Can Realistically Expect
- Cardiovascular, Prostate, and Blood Risks to Understand
- How Doctors Monitor BHRT for Men Over Time
- Bringing This to Your Consultation
- Common Questions Patients Ask After Starting
Why BHRT for Men Starts With the Right Diagnosis
Feeling tired doesn't automatically mean testosterone is low. Reduced motivation, poor sleep, depression, medication effects, chronic illness, relationship stress, calorie restriction, and temporary illness can create similar complaints. Testosterone also changes during the day, which is why a single random blood test shouldn't decide treatment.
A sound evaluation connects symptoms with laboratory evidence and medical history. Symptoms may involve sexual function, spontaneous erections, energy, body composition, mood, concentration, muscle mass, or bone health. The clinician should also ask when the symptoms began and whether another explanation fits better.
The diagnostic sequence matters
Major endocrine guidance emphasizes treatment for men with symptoms and unequivocally low laboratory values, rather than nonspecific complaints associated with aging. Earlier guidance recommended confirming the diagnosis with repeated morning measurements, and some international guidance has used a biochemical threshold near 231 ng/dL on two separate morning tests as part of the diagnostic process. These criteria are discussed in the Endocrine Society testosterone therapy guideline.
The scale of inappropriate sequencing is important. In a clinical study of 9,176 men, 3,320, or 36%, were identified as hypogonadal, with a mean total testosterone level of 194.3 ± 64.9 ng/dL. Yet only 17.7% of those men received testosterone replacement therapy, and monitoring was inconsistent. Only 40% of treated men had follow-up liver function tests and/or a complete blood count within 180 days, while 49% had a repeat testosterone level, according to the published clinical study.
What a responsible starting visit includes
Before discussing gels, injections, or pellets, a prescriber should review medications, sleep quality, possible sleep apnea, fertility plans, cardiovascular history, prior testosterone exposure, and prostate health. The broader framework for bioidentical hormone replacement therapy should remain individualized and evidence-aware.
Practical rule: A symptom can justify testing. It can't, by itself, justify testosterone.
Who Actually Qualifies for Male Hormone Therapy
A man may qualify when two conditions meet: he has symptoms or signs compatible with testosterone deficiency, and laboratory testing repeatedly shows low testosterone. Neither part should be skipped.
Start with symptoms, but don't stop there
Possible symptoms include reduced libido, erectile difficulties, fewer spontaneous erections, loss of body or facial hair, reduced muscle mass, increased body fat, low mood, and low-trauma fracture. These findings can be clinically meaningful, but they aren't exclusive to hypogonadism.
Insomnia, depression, chronic disease, medication effects, under-recovery from exercise, and persistent stress may produce the same concerns. A clinician should ask whether the symptoms appeared together, whether they progressed gradually, and whether they improve or worsen with sleep, illness, or medication changes.
Confirm the hormone result
The usual starting test is total testosterone obtained in the early morning, repeated on a separate day when possible. If the total value is close to the lower limit, or if altered sex hormone-binding globulin could distort interpretation, free testosterone may add useful context.
Further testing can help identify the reason for a low result:
- Gonadotropins: Luteinizing hormone and follicle-stimulating hormone help distinguish testicular causes from pituitary or hypothalamic causes.
- Prolactin: An elevated result can point toward a different endocrine problem that requires evaluation.
- Blood counts: Hematocrit provides an important baseline safety marker.
- Prostate assessment: PSA and examination are considered according to age, symptoms, and risk.
- Fertility discussion: Exogenous testosterone can suppress sperm production, so future conception plans must be addressed before treatment.
Testosterone shouldn't be used for nonspecific symptoms when levels are normal. It may also be unsafe in men with breast or prostate cancer, a palpable prostate abnormality, PSA above 3 ng/mL without urologic evaluation, untreated obstructive sleep apnea, severe lower urinary tract symptoms, or class III or IV heart failure, as outlined in the clinical guideline on testosterone therapy.
A consultation should also distinguish hormone treatment from unrelated wellness goals. For example, a medical weight-management discussion, including the practice's medical weight loss services, doesn't replace a hypogonadism evaluation.
Comparing FDA-Approved and Compounded Options
“Bioidentical” describes molecular structure, not automatically superior care. Some compounded products contain a hormone structurally identical to endogenous testosterone, but that label doesn't establish better safety, effectiveness, absorption, or monitoring performance.
FDA-approved testosterone products are manufactured with established quality controls, labeled indications, dosing instructions, and formulation-specific pharmacokinetic information. They may be delivered through routes such as transdermal gels, injections, patches, or pellets. That standardization makes laboratory interpretation and dose adjustment more predictable.
Compounded formulations can have a legitimate role when a commercial preparation isn't suitable, such as a clinically relevant excipient issue or a clinician-directed need for a customized preparation. The trade-off is greater uncertainty around concentration, consistency, release characteristics, purity, and dose accuracy.
| Factor | FDA-Approved Testosterone | Compounded BHRT |
|---|---|---|
| Evidence base | Supported by product-specific regulatory and clinical information | Evidence for compounded bioidentical preparations in men is limited |
| Standardization | Established manufacturing and labeled dosing | Greater formulation and batch variability may occur |
| Dose predictability | Generally more predictable for monitoring | Absorption and delivered dose may be less predictable |
| Customization | More limited to available formulations | May allow clinician-directed customization |
| Titration | Usually easier to adjust by formulation | Can be more difficult, especially with long-acting preparations |
| Clinical default | Generally preferred when suitable | Considered when a specific clinical need justifies compounding |
A review of compounded bioidentical hormone therapy found a dearth of high-quality research focused on safety, effectiveness, and performance, as summarized in the clinical review of compounded bioidentical hormones. The practical implication is straightforward: compounded products should be treated as formulation-variable interventions, not as more physiologic therapies.
Pellets deserve particular caution because the dose can be difficult to titrate after insertion, and removal isn't always simple. The right choice depends on absorption, convenience, cost, dosing control, fertility plans, and the ability to maintain stable serum levels. “Natural” isn't a substitute for measurable and reproducible.
Benefits Men Can Realistically Expect
Testosterone therapy can help men with confirmed hypogonadism, but the response depends on the starting deficiency, cause, formulation, adherence, concurrent health conditions, and whether the symptom was testosterone-related. Men whose levels are already in the mid-normal range rarely experience a meaningful change by pushing levels higher.
Sexual function usually offers the clearest signal
Libido and sexual interest are among the more consistently responsive areas when a genuine deficiency is present. Erectile quality may improve when low testosterone contributes to the problem, although erectile dysfunction can also involve vascular disease, medication effects, psychological factors, or other causes.
Changes in sexual interest may become noticeable earlier than changes in body composition or bone density. Improvement still shouldn't be used as proof that the original diagnosis was correct, because expectation, relationship factors, and other treatment changes can influence how a person feels.
Body composition takes sustained work
Men with deficiency may gain lean mass and reduce visceral fat over time. These changes generally require continued treatment alongside resistance training, adequate nutrition, sleep, and management of the underlying condition. Testosterone isn't a replacement for those foundations.
Bone density is a longer-horizon outcome. Changes assessed with DEXA may require extended treatment, and fracture risk depends on more than testosterone alone. Bone health should be evaluated in context, particularly when there has been a low-trauma fracture or other risk factor.
| Benefit domain | Typical onset | Evidence strength | Realistic magnitude |
|---|---|---|---|
| Libido and sexual interest | Often earlier than structural changes | Relatively consistent in confirmed deficiency | Meaningful improvement is possible, but not universal |
| Erectile quality | Variable | Moderate, because multiple causes may coexist | May improve when deficiency contributes |
| Lean mass and body composition | Usually months | Moderate | Gradual change, strengthened by resistance exercise |
| Bone density | Longer term | Clinically relevant in deficiency | Improvement may be modest and requires sustained management |
| Mood | Variable | Mixed | Some men report improvement, but causes of low mood must be assessed |
| Cognition and “brain fog” | Variable | Limited and difficult to isolate | Don't assume aging-related fog will respond |
| General fatigue | Variable | Weak when testosterone isn't clearly low | Poor response is common if another cause is present |
Joint pain, unexplained fatigue with normal testosterone, and cognitive complaints attributed only to aging often respond poorly. The same caution applies to broad promises about becoming younger, sharper, or stronger. Those claims go beyond what a diagnostic hormone treatment can reliably deliver. A broader wellness conversation, including peptide therapy and anti-aging solutions, should remain separate from the decision to treat confirmed hypogonadism.
Cardiovascular, Prostate, and Blood Risks to Understand
The safety conversation has become more nuanced, not irrelevant. Recent evidence has reduced support for blanket statements that properly managed testosterone therapy causes major cardiovascular events, but it hasn't made every patient a candidate or eliminated the need for blood-pressure and cardiovascular review.
A 2025 expert position statement concluded that testosterone therapy is cardiovascularly safe when prescribed for clinically confirmed hypogonadism and appropriately managed. A 2026 publication likewise reported improvements in sexual function, body composition, metabolic profile, and bone density without increased major cardiovascular events or prostate cancer risk in men with testosterone deficiency. The recent evidence review also reflects why selection and follow-up still matter.
Four safety categories shape the decision
Cardiovascular status deserves an individualized review. Fluid retention, blood-pressure changes, rhythm concerns, and the patient's existing cardiovascular disease can affect formulation and follow-up. The FDA's 2026 update emphasized treatment selection and blood-pressure monitoring rather than offering blanket reassurance, as described in the FDA testosterone therapy update.
Hematologic risk centers on erythrocytosis, an abnormal rise in red-cell concentration. Baseline hematocrit and repeat testing after treatment are essential. If the value rises substantially, the response may include dose reduction, a formulation change, temporary interruption, or evaluation for another cause. Routine phlebotomy shouldn't be used to excuse uncontrolled dosing.
Prostate monitoring includes PSA and examination when appropriate. Testosterone isn't treated as a cause of prostate cancer, but an existing prostate condition may worsen or become more clinically apparent during therapy. New urinary symptoms, a concerning examination, or a significant PSA change warrants assessment rather than automatic dose escalation.
Fertility is the risk many men discover too late. Exogenous testosterone can suppress the hormonal signaling that supports sperm production. A man who may want to conceive should discuss alternatives with a clinician experienced in male fertility before starting.
| Risk category | Key marker or event | Action threshold | Typical response |
|---|---|---|---|
| Cardiovascular | Blood pressure, edema, rhythm symptoms, cardiovascular history | Clinically significant change or concerning symptoms | Reassess dose, formulation, and cardiovascular status |
| Hematologic | Hemoglobin and hematocrit | Rising hematocrit, particularly above the guideline threshold of 0.54 | Reduce dose, change preparation, or pause and evaluate |
| Prostate | PSA, urinary symptoms, examination findings | Concerning PSA change, nodule, or worsening urinary symptoms | Urologic evaluation before continuation or escalation |
| Fertility | Sperm production and conception plans | Current or near-term fertility goals | Avoid routine exogenous testosterone and discuss fertility-directed care |
How Doctors Monitor BHRT for Men Over Time
A prescription becomes controlled medical treatment only when the clinician can measure exposure, response, and adverse effects. Monitoring shouldn't be added after a problem appears. It should be designed before the first dose.
Establish a meaningful baseline
A typical baseline review may include:
- Morning total testosterone, with free testosterone and SHBG when interpretation requires them
- LH, FSH, prolactin, and selected additional endocrine tests
- CBC with hematocrit
- Full metabolic panel and lipids
- PSA when clinically appropriate
- Blood pressure, cardiovascular history, sleep apnea screening, and fertility planning
The exact panel depends on the patient. More testing isn't automatically better, but unexplained low testosterone should not be treated without considering why it is low.
Match blood-test timing to the formulation
Testosterone levels are commonly checked 3 to 6 months after initiation, with the exact timing based on the preparation. Injectable enanthate or cypionate may be measured midway between injections, while transdermal gel testing is performed 2 to 8 hours after application once steady state has been reached. A clinical monitoring framework for male testosterone therapy explains why timing matters.
An early follow-up visit reviews symptoms, adherence, side effects, blood pressure, and the actual time of the last dose or application. A later safety checkpoint reviews hematocrit and PSA when appropriate. Stable patients still need ongoing review, because weight, sleep, medications, cardiovascular status, and fertility goals can change.
Evidence-based targets generally aim for the mid-normal range, not the highest tolerated level. One guideline framework recommends dose adjustment when mid-interval testosterone is above 600 ng/dL or below 350 ng/dL, while hematocrit above 0.54 should prompt action. These thresholds support reassessment, not automatic treatment escalation.
Bringing This to Your Consultation
The most useful consultation starts with organized information rather than a preferred product. Bring a symptom timeline, prior laboratory results, a complete medication and supplement list, and a clear statement about whether you may want children.
Questions worth asking
- Diagnostic standard: How does the clinician define hypogonadism, and will testosterone be measured twice on separate mornings?
- Alternative explanations: Could sleep apnea, depression, medication effects, chronic illness, or another endocrine problem explain the symptoms?
- Fertility impact: Could treatment suppress sperm production, and what options exist if conception is planned?
- Product selection: Is an FDA-approved formulation appropriate? If compounding is being considered, what specific clinical need does it address?
- Monitoring plan: When will testosterone, hematocrit, PSA, blood pressure, and symptom response be reassessed?
- Stopping criteria: Which laboratory changes, symptoms, or examination findings would lead to dose reduction, switching, referral, or pausing treatment?
You can evaluate your goals, symptom pattern, adherence, side effects, and willingness to attend follow-up. You can't determine candidacy from symptoms alone, interpret every laboratory result without context, or safely choose a dose based on how energetic you feel after one application.
A careful clinician should explain how test timing relates to the formulation, what “mid-normal” means in the treatment plan, and how fertility goals change the decision. The consultation should feel like a risk-benefit discussion, not a confirmation of a purchase you made online.
The best question isn't “Which pellet is strongest?” It's “What diagnosis are we treating, and how will we know the treatment remains safe?”
Common Questions Patients Ask After Starting
How is the starting dose chosen?
The starting dose depends on the formulation, baseline testosterone, symptom goals, age, cardiovascular risk, prostate considerations, fertility plans, and laboratory response. It shouldn't be selected to recreate a youthful concentration or to chase a subjective feeling of intensity.
How long does treatment continue?
Testosterone is generally continued only when benefits remain meaningful, side effects are acceptable, and monitoring remains reassuring. It shouldn't be continued just because it was started, and it shouldn't be stopped or tapered automatically without discussing the reason and the expected consequences with the prescriber.
A man may need a different preparation if absorption is inconsistent, levels are too high or too low, hematocrit rises, or the route conflicts with his lifestyle. Dose changes should consider the time since application or injection, symptoms, measured testosterone, and safety results together.
What about trying to conceive?
Men trying to conceive should generally avoid exogenous testosterone because it can suppress sperm production. Speak with a clinician specializing in male infertility or reproductive endocrinology before treatment begins, especially if conception is a current or near-term goal.
What should follow-up look like?
A practical schedule includes an early safety review, formulation-specific testosterone testing, hematocrit assessment, and prostate or cardiovascular reassessment when clinically indicated. Improvement in some symptoms may take months, while erythrocytosis can develop sooner, so feeling better doesn't prove that the dose is safe.
Seek prompt medical care for chest pain, severe shortness of breath, neurologic symptoms, marked swelling, urinary obstruction, or another concerning reaction. Contact the prescribing clinician about persistent headaches, worsening sleep-disordered breathing, significant urinary changes, or other new symptoms.
The FDA's treatment position remains specific: approved testosterone products are indicated for men with particular forms of hypogonadism, while emerging evidence may support consideration in some men with idiopathic low libido. A 2026 Endocrine Society report also highlighted that only a small number of men prescribed testosterone received appropriate guideline-concordant diagnostic testing, reinforcing the need to verify the diagnosis before focusing on dose or delivery method.
Medical Aesthetics And Lasers offers physician-led evaluation and Bioidentical Hormone Replacement Therapy for adults seeking care for symptomatic hormonal imbalance, with treatment decisions based on individualized history, laboratory findings, and follow-up planning. Visit Medical Aesthetics And Lasers to schedule a consultation and bring your symptom timeline, prior testosterone results, medication list, and fertility questions to the discussion.